ALZN Form 4: Milton C. Ault III Discloses Multiple September 2025 Sales
Rhea-AI Filing Summary
Milton C. Ault III, identified as a director and a 10% owner of Alzamend Neuro, Inc. (ALZN), reported multiple sales of the company’s common stock in late September 2025. The filings show sales on 09/26/2025 of 37,738 shares at $2.3145, on 09/29/2025 of 38,324 shares at $2.309, and on 09/30/2025 of 3,566 shares at $2.3334. After those transactions, beneficial ownership reported for the related entities was 73,516 shares (indirect) by Ault Lending, LLC, 35,192 shares (indirect) by Ault Lending, LLC, and 31,626 shares (indirect) by Ault Lending, LLC, respectively. Additional holdings include 11,068 shares held indirectly by Ault Life Sciences, Inc. and 61 shares indirectly by Ault Life Sciences Fund, LLC. The Form 4 is signed by Mr. Ault on 09/30/2025.
Positive
- Clear, itemized disclosure of transaction dates, share counts, and prices satisfying Section 16(a) reporting requirements
- Explanatory notes identify indirect ownership structures (Ault Lending, Ault Life Sciences, Ault Life Sciences Fund)
Negative
- Significant insider dispositions are reported (totaling 79,628 shares sold across 09/26–09/30/2025 as listed in Table I)
- Majority ownership held indirectly which may complicate direct transparency of individual holdings
Insights
TL;DR: Multiple insider sales by a director/10% owner are disclosed; ownership is largely indirect through affiliated entities.
Mr. Ault, serving as director and a 10% owner, reported several dispositions of common stock across three dates in late September 2025. The filings clearly attribute indirect beneficial ownership to affiliated entities (Ault Lending, LLC; Ault Life Sciences, Inc.; Ault Life Sciences Fund, LLC) and explain voting and investment power where applicable. From a governance perspective, the disclosure meets Section 16(a) reporting requirements by itemizing transaction dates, share amounts, and prices, and by providing explanatory footnotes on control of record holders.
TL;DR: The Form 4 reports routine insider sales with specific share counts and prices; holdings remain consolidated in related entities.
The report documents specific sale prices ranging from $2.309 to $2.3334 and lists resulting beneficial ownership amounts for the reporting entities. It also clarifies the chain of control: Ault Lending is a wholly-owned HSD subsidiary with Mr. Ault deemed to have voting and investment power, while other holdings are directly controlled by Mr. Ault. The filing is precise on quantities and prices, enabling exact calculation of proceeds from the disclosed transactions if needed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,566 | $2.3334 | $8K |
| Sale | Common Stock | 38,324 | $2.309 | $88K |
| Sale | Common Stock | 37,738 | $2.3145 | $87K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
